A San Diego biotechnology company has been refused a trademark registration for ‘Sequencing by Binding’ on the grounds that it is too descriptive.
A US federal judge has given preliminary approval to the proposed settlement in the class action suit led by Nashville General Hospital against Momenta Pharmaceuticals and Sandoz over their alleged manipulation of drug testing protocols.
A group of generics manufacturers yesterday, December 2 asked the US Court of Appeals for the Ninth Circuit to reverse California’s ban on pay-for-delay deals.
Gene-sequencing companies Illumina and Pacific Biosciences have “mutually agreed” to terminate their $1.2 million merger agreement, under which Illumina would have acquired PacBio.
California-based Adamas Pharmaceuticals has entered into a settlement agreement with Novartis’ generics unit Sandoz over a treatment for dyskinesia, the involuntary movements in Parkinson’s disease patients.
Eli Lilly has won a victory in a cancer drug dispute after a federal judge ruled that Canadian pharmaceutical company Apotex’s new drug application infringed the company’s patent.
A New York-based cardiologist is suing Apple over the tech that allows the Apple Watch to detect irregular heart rhythms.
The US Patent and Trademark Office has granted the University of California its 20th US patent on CRISPR-Cas9 gene-editing technologies.
Sandoz and Momenta have agreed to pay $120 million to bring an antitrust class action over blockbuster blood clot drug enoxaparin to an end.
Johnson & Johnson has announced its plan to acquire the remaining stake in Verb Surgical, its robotics venture with Alphabet-owned Verily.